Diagenode
Hologic Reports Gains in Non-COVID Diagnostics, Surgical Products
Company beats its Q3 earnings guidance on strength of women's health diagnostics income, and CEO Steve MacMillan predicted relief from chip supply problems
Hologic Preliminary Fiscal Q1 Revenues Drop 9 Percent
The firm expects fiscal Q1 Diagnostics revenues of $950.4 million, down 16 percent compared to the prior-year quarter when its COVID-19 revenues surged.
The company has invested revenues from its pandemic testing business to buy assets that are growing faster than its base business.
Diagenode already sells more than 30 real-time PCR tests that are CE-marked for the detection of bacteria, parasites, and viruses for multiple infectious diseases.
Siemens Healthineers, Roche Diagnostics, BioMérieux, Cepheid, and Others Receive FDA Clearances in July
Siemens Healthineers received FDA clearances for several assays, including separate allowances for tests using hemoglobin A1c, troponin I, and procalcitonin biomarkers.